Clorox stock’s consensus analyst price target has seen a slight adjustment, declining from $124.76 to $124.59. This modest reduction reflects the balance between cautious optimism and ongoing concerns regarding the company’s near-term outlook. Stay tuned for insights on how you can keep informed as the market narrative for Clorox continues to evolve.

Stay updated as the Fair Value for Clorox shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Clorox.

Analyst commentary in recent weeks has reflected a balanced but cautious stance on Clorox, as multiple firms adjusted their price targets following softer-than-expected quarterly performance and subdued guidance.

???? Bullish Takeaways

Morgan Stanley’s Dara Mohsenian lowered the price target to $125 from $137 but noted that Clorox’s Q1 results and FY guidance were "not as bad as feared," reflecting some resilience in the face of soft results.

Several firms express that near-term headwinds, such as muted sales growth and operational disruptions, are being recognized and managed, pointing to ongoing improvement efforts by management.

Despite broader estimate cuts across consumer staples, BofA maintains a Neutral rating and a revised $125 price target, underscoring a measured stance rather than outright negativity.

???? Bearish Takeaways

Wells Fargo downgraded its price target to $117 from $125, signaling continued caution around Clorox’s soft Q1 results and FY26 guidance. The firm awaits more concrete progress in the second half of the year before its narrative can turn more positive.

TD Cowen dropped its target to $117 from $120 and highlighted that ongoing service disruptions and weak organic sales growth remain material pressures on valuation and sentiment.

Barclays lowered its target to $112 from $118, citing “muted and decelerating” growth across parts of the personal care business and maintaining an Underweight rating.

Together, the analyst reactions encapsulate a market that recognizes Clorox’s operational challenges and awaits clearer signs of improvement before adjusting to a more optimistic outlook on valuation or sustained growth.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Clorox has reaffirmed its earnings guidance for Fiscal Year 2026, projecting a net sales decline of 6% to 10% and diluted EPS between $5.60 and $5.95. This equates to a year-over-year decline of 14% to 9%.

The company executed another tranche of its ongoing stock buyback program by repurchasing 329,084 shares for $39.9 million between July and September 2025. Cumulative repurchases under the current program now stand at 8,395,307 shares.

CloroxPro introduced Clorox Screen+ Sanitizing Wipes, a new cleaning solution specifically developed to safely sanitize digital screens and electronics. This reflects expanded efforts to support evolving cleaning needs in technology-driven work environments.

Consensus analyst price target has declined slightly, moving from $124.76 to $124.59.

The discount rate has risen modestly, increasing from 6.78% to 6.96%.

The revenue growth estimate is virtually unchanged, remaining around 1.43%.

The net profit margin has fallen marginally, slipping from 12.46% to 12.35%.

The future P/E ratio has increased moderately, rising from 20.02x to 20.62x.

Narratives are powerful stories created by investors like you that put Clorox’s numbers into context. They connect a company’s evolving story to a financial forecast and fair value, helping you judge if the current price makes sense. Simply Wall St’s Community page makes following and comparing these narratives easy, so you can quickly see when new information changes the outlook and whether it’s time to buy, hold, or sell.

Read the original Clorox narrative for a full-picture view. Here’s why you should keep up with it:

See whether Clorox’s digital transformation and cost controls could drive a rebound in growth and earnings from 2026 onward.

Understand how ongoing innovation and premium products might help Clorox recover market share and boost profitability despite tough industry competition.

Track what could go wrong, such as price wars, shifting consumer preferences, or supply chain setbacks, and how these risks might impact future fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com